Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7326/M21-0111 http://scihub22266oqcxt.onion/10.7326/M21-0111 33460347!7839932!33460347     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Intern+Med 2021 ; 174 (5): 687-690 Nephropedia Template TP {{tp|p=33460347|t=2021. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn |pdf=|usr=}}{{33460347}} gab.com Text SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn JO: Ann Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33460347 #FOAvip As COVID vaccines roll out, internists and other health care providers are being turned to as trusted sources of information for patients and communities. Here, experts from NIAID outline the current state of knowledge regarding such vaccines. They contrast vaccine platforms, summarize clinical trial data regarding efficacy and safety, and comment on key questions including the ability of current vaccines to protect against infection and to decrease the prevalence of virus in the community. Twit Text FOAVip SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn ????Ann Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33460347 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33460347 #FOAvip English Wikipedia <ref>{{Cite pmid|33460347}}</ref> SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn #MMPMID33460347 Connors M; Graham BS; Lane HC; Fauci AS Ann Intern Med 2021[May]; 174 (5): 687-690 PMID33460347show ga As COVID vaccines roll out, internists and other health care providers are being turned to as trusted sources of information for patients and communities. Here, experts from NIAID outline the current state of knowledge regarding such vaccines. They contrast vaccine platforms, summarize clinical trial data regarding efficacy and safety, and comment on key questions including the ability of current vaccines to protect against infection and to decrease the prevalence of virus in the community. |COVID-19 Vaccines/*immunology[MESH] |COVID-19/immunology/*prevention & control[MESH] |Clinical Trials as Topic[MESH] |Humans[MESH] |Immunogenicity, Vaccine[MESH] |Pandemics/prevention & control[MESH] |Patient Safety[MESH] |Pneumonia, Viral/immunology/*prevention & control/virology[MESH] |SARS-CoV-2/immunology[MESH] |United States[MESH] |United States Food and Drug Administration[MESH] |Vaccines, Synthetic/*immunology[MESH] |Viral Vaccines/immunology[MESH]SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn (epmc).pdf DeepDyve Pubget Overpricing